Australian researchers released Cardiopedia-Ligand, a comprehensive online database mapping how human heart tissue responds to 87 signaling molecules. Published in Cell Stem Cell, the five-year project uses laboratory-grown cardiac organoids to provide an open-access reference tool for scientists studying heart disease treatments and personalized therapies.
A team led by Australia’s QIMR Berghofer Medical Research Institute spent five years constructing a public reference database designed to change how scientists analyze cardiac function.
The newly launched platform, named Cardiopedia-Ligand, catalogues how laboratory-grown human heart tissues respond to 87 biological signaling molecules that interact with cellular receptors. Researchers used human cardiac organoids—miniature heart tissues grown in a lab setting—to measure how strongly the tissue contracted and which genes turned on or off during exposure to each molecule.
Mapping Cellular Communication in Lab-Grown Heart Tissue
The new atlas compiles biological signaling molecules into a single, unified dataset that allows direct comparisons of their similarities and differences.
“For the first time, we’ve brought all that information together into a single resource that researchers can use to better understand heart disease.”
Prof. James Hudson, head of QIMR Berghofer’s Cardiac Bioengineering Laboratory
The findings from this five-year effort have been published in Cell Stem Cell, establishing an open-access baseline for investigators worldwide. By making the atlas publicly available online, the QIMR Berghofer team aims to accelerate global discoveries related to cardiac health and pharmaceutical interventions.
Screening 2,000 Drug Compounds in the Next Phase
The newly published dataset represents only the first phase of a broader scientific initiative. With the initial mapping complete, the research team is preparing for a follow-up stage focused on pharmacology and targeted treatments.
Investigators plan to screen about 2,000 drug compounds to build a more expansive map detailing how heart biology responds to potential therapeutic agents. This upcoming screening effort is designed to address limitations in current heart failure treatments.
“The goal is to increase the number of drugs that are effective for heart failure that actually act on the heart tissue. The grand vision of the project is that, for personalized medicine, someone can go to the hospital and their genetics and biomarkers are exactly matched to an effective drug.”
Prof. James Hudson, head of QIMR Berghofer’s Cardiac Bioengineering Laboratory
Broader Institutional Efforts in Structural Heart Research
Cardiovascular research centers maintain active programs to evaluate new diagnostic techniques, imaging methods, and targeted treatments for structural heart conditions. Programs such as the Structural Heart Disease Program in the Cardiovascular Research Center investigate congenital heart disease, hypertrophic cardiomyopathy, Marfan syndrome, pericardial disease, and valvular heart disease.
These specialized clinical programs utilize advanced imaging tools like echocardiography, computerized tomography, and magnetic resonance imaging alongside artificial intelligence-enabled methods and biomarkers to refine patient risk stratification. By integrating electronic patient databases with multicenter U.S. clinical trials evaluating minimally invasive transcatheter devices and novel medications, researchers continue to track clinical outcomes, hospitalization rates, and optimal intervention timings across community and referral populations.
